Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06684561

EARLY FEASIBILITY STUDY: SAFETY AND EFFICACY OF PHOTON INFUSION SET

Study 1:

The purpose of this study is to evaluate safety and efficacy of Photon infusion sets (PIS) with new PFAS-free cannula (catheter) in adult patients with Type 1 diabetes for up to 10 days and 6 hours.

This is a 1-center, prospective, open-label, 1-arm study with type 1 patients with diabetes on 780G insulin pump therapy with Guardian™ 4 Continuous Glucose Monitoring (CGM). All subjects will be instructed to change infusion sets every 246 hours (10 days & 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.

After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of <6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.

Photon infusion sets with 6-mm and 9-mm cannula length will be supplied for this study, with selection based on subjects' needs and doctor's recommendation. Subjects will change insulin reservoirs at least every 7 days (the labelled wear duration of the Extended reservoir). The infusion set(s) or reservoir(s) can be replaced independent of each other. The date and time of each infusion set insertion will be recorded in a Daily Log (Diary) which will include the causes of early removal, if occurs.

Study 2: If Study 1 is successful, the same study designed as illustrated in Figure 1 may be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of type 1 diabetes for at least one year
  • Using a MiniMed™ 780G Insulin pump with Guardian sensor
  • Age 18 to 80 years
  • Hemoglobin A1c level less than or equal to 10%
  • Not currently known to be pregnant, nor planning pregnancy during the study.
  • Willingness to follow the protocol and sign the informed consent

Exclusion criteria

  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
  • Pregnant or lactating females
  • Subject has Glycosylated hemoglobin (HbA1c)< 10 % at time of screening.

Treatment and study plan

PIS

Device

All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days & 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.

defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of <6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.

if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users

Primary outcomes

  1. Primary Effectiveness Endpoint

    Time frame: 12 months

    The primary outcome is to have no more than 16% of infusion set failures due to "unexplained hyperglycemia" Definition of unexplained hyperglycemia: o The study meter glucose >250 mg/dL (>3 hours post-meal) which may include time during subject's sleeping hours.

    • Failure of a correction dose(s) to lower the study meter glucose by at least 50 mg/dL within 1 hour.
    • One additional correction dose may be given after first correction dose and recommended to use the bolus calculator

Study contacts

Contact information is provided by the study sponsor or research team.

Maya Hirsh Maya Laron Hirsh Study coordinator, M.Sc

CONTACT

[email protected]

[email protected]

Sapir Barel

CONTACT

[email protected]

0526177726

Sponsors and collaborators

Lead sponsor

Sheba Medical Center

Other Gov

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 12, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.